期刊文献+

Towards efficiency in rare disease research: what is distinctive and important? 被引量:3

Towards efficiency in rare disease research: what is distinctive and important?
原文传递
导出
摘要 Characterized by their low prevalence, rare diseases are often chronically debilitating or life threatening. Despite their low prevalence, the aggregate number of individuals suffering from a rare disease is estimated to be nearly 400 million worldwide.Over the past decades, efforts from researchers, clinicians, and pharmaceutical industries have been focused on both the diagnosis and therapy of rare diseases. However, because of the lack of data and medical records for individual rare diseases and the high cost of orphan drug development, only limited progress has been achieved. In recent years, the rapid development of next-generation sequencing(NGS)-based technologies, as well as the popularity of precision medicine has facilitated a better understanding of rare diseases and their molecular etiology. As a result, molecular subclassification can be identified within each disease more clearly, significantly improving diagnostic accuracy. However, providing appropriate care for patients with rare diseases is still an enormous challenge. In this review, we provide a brief introduction to the challenges of rare disease research and make suggestions on where and how our efforts should be focused. Characterized by their low prevalence, rare diseases are often chronically debilitating or life threatening. Despite their low prevalence, the aggregate number of individuals suffering from a rare disease is estimated to be nearly 400 million worldwide.Over the past decades, efforts from researchers, clinicians, and pharmaceutical industries have been focused on both the diagnosis and therapy of rare diseases. However, because of the lack of data and medical records for individual rare diseases and the high cost of orphan drug development, only limited progress has been achieved. In recent years, the rapid development of next-generation sequencing(NGS)-based technologies, as well as the popularity of precision medicine has facilitated a better understanding of rare diseases and their molecular etiology. As a result, molecular subclassification can be identified within each disease more clearly, significantly improving diagnostic accuracy. However, providing appropriate care for patients with rare diseases is still an enormous challenge. In this review, we provide a brief introduction to the challenges of rare disease research and make suggestions on where and how our efforts should be focused.
出处 《Science China(Life Sciences)》 SCIE CAS CSCD 2017年第7期686-691,共6页 中国科学(生命科学英文版)
基金 supported by the National High Technology Research and Development Program of China (2015AA020108, 2015AA020104) the National Science Foundation of China (31671377) Shanghai 111 Project (B14019)
关键词 疾病 研究人员 制药行业 临床医生 开发费用 患病率 患者 诊断 rare disease rare disease diagnosis and treatment data standard data sharing orphan drugs
  • 相关文献

参考文献1

二级参考文献14

  • 1Amato, P., Tachibana, M., Sparman, M., and Mitalipov, S. (2014). Three-parent in vitro fertilization: gene replacement for the prevention of inherited mitochondrial diseases. Fertil Steril 101, 31-35.
  • 2Bacman, S.R., Williams, S.L., Pinto, M., Peralta, S., and Moraes, C.T. (2013). Specific elimination of mutant mitochondrial genomes in pa- tient-derived cells by mitoTALENs. Nat Med 19, 1 l 11-1113.
  • 3Comte, C., Tonin, Y., Hecket-Mager, A.M., Boucheham, A., Smirnov, A., Aure, K., Lombes, A., Martin, R.P., Entelis, N., and Tarassov, 1. (2013). Mitochondrial targeting of recombinant RNAs modulates the level of a heteroplasmic mutation in human mitochondrial DNA associ- ated with Kearns Sayre Syndrome. Nucleic Acids Res 41,418-433.
  • 4Ma, H., Folmes, C.D., Wu, J., Morey, R., Mora-Castilla, S., Ocampo, A., Ma, L., Poulton, J., Wang, X., Ahmed, R., Kang, E., Lee, Y., Hayama, T., Li, Y., Van Dyken, C., Gutierrez, N.M., Tippner-Hedges, R., Koski, A., Mitalipov, N., Amato, P., Wolf, D.P., Huang, T., Terzic, A., Lau- rent, L.C., Izpisua Belmonte, J.C., and Mitatipov, S. (2015). Metabolic rescue in pluripotent cells from patients with mtDNA disease. Nature 524, 234-238.
  • 5Prigione, A. (2015). Induced pluripotent stem cells (iPSCs) for modeling mitochondrial DNA disorders. Methods Mol Biol 1265, 349-356.
  • 6Reddy, P., Ocampo, A., Suzuki, K., Luo, J., Bacman, S.R., Williams, S.L., Sugawara, A., Okamura, D., Tsunekawa, Y., Wu, J., Lam, D., Xiong, X., Montserrat, N., Esteban, C.R., Liu, G.H., Sancho-Martinez, l., Ma- nau, D., Civico, S., Cardellach, F., Del Mar O'Callaghan, M., Campis- tol, J., Zhao, H., Campistol, J.M., Moraes, C.T., and lzpisua Belmonte, J.C. (2015). Selective elimination of mitochondrial mutations in the germline by genome editing. Cell 16l, 459-469.
  • 7Schon, E.A., DiMauro, S., and Hirano, M. (2012). Human mitochondrial DNA: roles of inherited and somatic mutations. Nat Rev Genet 13, 878-890.
  • 8Sung, Y.H., Baek, l.J., Kim, D.H., Jeon, J., Lee, J., Lee, K., Jeong, D., Kim, J.S., and Lee, H.W. (2013). Knockout mice created by TALEN-mediated gene targeting. Nat Biotechnol 31, 23-24.
  • 9Tachibana, M., Sparman, M., Sritanaudomchai, H., Ma, H., Clepper, L., Woodward, J., Li, Y., Ramsey, C., Kolotushkina, O., and Mitalipov, S. (2009). Mitochondrial gene replacement in primate offspring and em- bryonic stem cells. Nature 461,367 372.
  • 10Taylor, R.W., Chinnery, P.F., Turnbull, D.M., and Lightowlers, R.N.(1997). Selective inhibition of mutant human mitochondrial DNA rep- lication in vitro by peptide nucleic acids. Nat Genet 15, 212-215.

共引文献2

同被引文献23

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部